Our proprietary mVECTATM platform enables us to design and screen for highly selective drug molecules that engage the MFSD2A transport protein making them highly brain penetrant. We believe our platform which leverages molecular properties of the MFSD2A transporter, enables us to discover and develop new chemical entities that optimize three essential elements: a MFSD2A binding moiety, a parent drug with known target engagement, and a combination of linkers connecting the two. These key components of the mVECTATM platform described below combine our broad understanding of the physiological and biochemical function of MFSD2A at the blood-brain-barrier and in specific cell types of the brain allowing for target access in cells and subcellular compartments that were once inaccessible.
- MFSD2A Brain Cell Map
With the support of the Duke-NUS Medical School and David Silver’s lab, we have mapped the location and function of MFSD2A in cell types across the brain and its role in key biological pathways. This knowledge enables us to match drug candidate with desired target pathway found in specific types of MFSD2A expressing cells throughout the brain.
- Vector Toolbox
Our MFSD2A whole brain cell map together with the Silver lab’s atomic resolution structure of the MFSD2A protein has allowed us to generate a toolbox of proprietary vectors to expand the library of MFSD2A transported molecules with enhanced brain penetration capabilities.
- Proprietary Chemistry
Our expertise in MFSD2A proprietary ligand chemistry allows us to design drug molecules with optimized pharmaceutical properties tailored to specific indications and patient populations
- Quantitative Pharmacology
Our proprietary in vitro cell assays and humanized MFSD2A transgenic mouse models combined with our understanding of PK/PD relationships of our drug molecules allows us to model key parameters that tune pharmacodynamics to the site of action.
- Proprietary Modelling
Our structural biology information combined with biochemical and computational characterization of MFSD2A drug engagement is used to prospectively design and select candidates.